CRISPR Therapeutics AG - Common Shares (CRSP) Covered Calls
You can sell covered calls on CRISPR Therapeutics AG - Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CRSP (prices last updated Wed 4:16 PM ET):
CRISPR Therapeutics AG - Common Shares (CRSP) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
41.06 | -3.57 | 41.00 | 41.30 | 2.3M | - | 3.8 |
Covered Calls For CRISPR Therapeutics AG - Common Shares (CRSP) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Dec 20 | 41 | 0.70 | 40.60 | 1.0% | 122% | |
Jan 17 | 40 | 3.20 | 38.10 | 5.0% | 58.9% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | NVDA covered calls | 6. | EEM covered calls | 1. | NVDA covered calls | |
2. | SPY covered calls | 7. | IWM covered calls | 2. | RGTI covered calls | |
3. | XLF covered calls | 8. | KWEB covered calls | 3. | QUBT covered calls | |
4. | QQQ covered calls | 9. | TLT covered calls | 4. | MU covered calls | |
5. | FXI covered calls | 10. | TSLA covered calls | 5. | QBTS covered calls |
Want more examples? CRS Covered Calls | CRSR Covered Calls